Caresyntax, the leading enterprise-level digital surgery platform delivering actionable insights to make surgery smarter and safer, today announced a $30 million extension to its Series C funding round, initially led by PFM Health Sciences, LP. Selected investors include funds and accounts managed by BlackRock, as well as ProAssurance, Harmonix, and existing investors such as the Relyens Group and IPF Partners.

The additional investment brings the total Series C funding to $130 million, building on the first stage announced in April 2021. That round also included investments from Optum Ventures, Intel Capital, Lauxera Capital Partners, Vesalius Biocapital III, Arno Capital, Rezayat Investments, and Surgical.AI. The funding will be used to continue developing its platform as well as advance new data solutions that support value-based care providers.

Caresyntax is on a mission to make surgery smarter and safer. Our enterprise-grade digital surgery platform delivers actionable insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around the OR. This real-world evidence can be used by the care team live, during a procedure and accessed by those outside the operating room via the platform's dedicated telehealth link. After a procedure, the Caresyntax platform provides insights that help: surgeons benchmark and improve their care, hospital administrators use surgical resources more efficiently, medical device companies advance better products, and insurance companies understand risk and devise more tailored policies. Founded by entrepreneurs Dennis Kogan and Björn von Siemens, Caresyntax software is used in more than 4,000 operating rooms worldwide and supports surgical teams in over two million procedures per year.